论文部分内容阅读
目的 :观察比较TP(Taxol、DDP) ,MNP(MMC、NVB、DDP)和MVP(MMC、VDS、DDP)联合化疗治疗晚期非小细胞肺癌的近期疗效和耐受性。方法 :110例晚期非小细胞肺癌接受三种不同化疗方案治疗 ,TP组 2 7例 ,MNP组40例 ,MVP组 43例。结果 :TP组有效率 5 1 9% ,中位缓解期 9 0个月 ,中位生存期 11 2个月 ;MNP组有效率为45 0 % ,中位缓解期 8 0个月 ,中位生存期 10 5个月 ;MVP组有效率 32 6 % ,中位缓解期 6 8个月 ,中位生存期 8 1个月。TP、MNP方案有效率高于MVP方案 ,但统计学无显著差异。主要毒性为骨髓抑制、恶心呕吐和脱发。结论 :本研究结果表明 ,泰素加顺铂治疗晚期非小细胞肺癌疗效较好 ,毒性反应可耐受 ,是目前治疗NSCLC的首选方案之一。
OBJECTIVE: To observe the short-term efficacy and tolerability of combination of TP (Taxol, DDP), MNP (MMC, NVB, DDP) and MVP (MMC, VDS, DDP) with chemotherapy in the treatment of advanced non-small cell lung cancer. Methods: One hundred and ten patients with advanced NSCLC were treated with three different chemotherapeutic regimens. There were 27 cases in TP group, 40 cases in MNP group and 43 cases in MVP group. Results: The effective rate of TP group was 51.9%, the median remission period was 90 months, and the median survival time was 11 2 months. The effective rate of MNP group was 45%, the median remission period was 80 months, and the median survival time Term 10 5 months; MVP group effective 32 6%, the median remission of 6 8 months, the median survival of 8 1 months. TP, MNP program is more efficient than MVP program, but no significant difference in statistics. The main toxicity is myelosuppression, nausea and vomiting and hair loss. Conclusion: The results of this study indicate that the combination of taxol and cisplatin in advanced non-small cell lung cancer is effective and tolerable. It is one of the first choice for the treatment of NSCLC.